Menu

Clinical Research

Clinical investigator, Dr. Dore participates as a Principal Investigator in clinical research studies of medications for treatment of gout, osteoarthritis, osteoporosis, rheumatoid arthritis, Lupus, metabolic bone and other auto-immune diseases. She has investigated multiple phase trials for over the last 30+ years.  Studied agents include, but not limited to: anti-TNF, anti-IL1, COX-2, RANK ligand inhibitor, selective estrogen receptor modulator, parathyroid hormone, Anti-Blyss antibodies, anti- IL-17, anti-IL-23 and other agents.

Please click here to find out about Current Enrolling Studies.

To CONTACT US:

Robin K. Dore, MD, Inc.
Clinical Research
12791 Newport Ave., Suite 201
Tustin, CA 92780

T.714.505.5500
F.714.505.3381
Email: research@robinkdoremd.com

Dr Dore’s studies are summarized below.

Ongoing and Past Clinical Research Study Collaborative Protocols Summary

2000-Current:

AbbVie (Abbott):

  • ABT-494 (JAK), multi center, randomized, treatment for RA: 2015→ongoing
  • adalimumab, multi center, randomized, treatment for RA, extension studies
  • adalimumab, multi center, randomized, treatment for Axial Spondyloarthritis

Amgen:

  • brodalumab, multi center, randomized, treatment for PsA
  • romosozumab, multi center, randomized, treatment for OP
  • denosumab multi center, randomized, treatment for OP
  • etanercept multi center, randomized, treatment for RA; open label extension study
  • anakinra, multi center, randomized, treatment for RA
  • etanercept, multi center, etanercept and MTX, mono/combo therapy, PsA; 2015→ongoing

AztraZenca:

  • fostamatinib disodium, multi center, randomized, treatment for RA

Bristol-Myers Squibb:

  • SQ abatacept, multi center, randomized, treatment for early RA

Biogen:

  • 2-Part, multi center, Eval safety and efficacy of sq BIIB059, SLE/CLE, 2016→ongoing

Eli Lilly & Co.:

  • ixekizumab, multi center, randomized, treatment for PsA: 2015→ongoing
  • arzoxifene, multi center, randomized, treatment for OP
  • teriparatide, multi center, randomized, tx for; OP, GIOP, device, observational
  • raloxifene, multi center, randomized, treatment for OP

GlaxoSmithKline:

  • GW406381 (cox-2) multi center, randomized, treatment for RA
  • belimumab, Auto-injector Device, multi center, SLE subjects

 HMR:

  • risedronate, multi center, randomized, treatment for OP; compliance

Human Genome Science/GSK:

  • belimumab, multi center, randomized, treatment for SLE

Knoll:

  • RA observational trial for RA meds

Merck:

  • alendronate, multi center, randomized, treatment for OP
  • rofecoxib, multi center, randomized, treatment for RA
  • zostavax, multi center, randomized, treatment for shingles vaccination

Novartis:

  • secukinumab, multi-center, safety/efficacy of secukinumab, PsA, 2016→ongoing

NPS Allelix:

  • PTH 1-84, multi center, randomized, treatment for OP

Optime:

  • liposome-encapsulated diclofenac analgesic (LEDA) multi center, randomized, treatment for OA knee

Oxford Outcomes:

  • Osteoporosis Questionnaire validation studies

Pfizer:

  • tofacitinib, 5mg multi center, randomized, treatment for RA; 2014→ongoing
  • tofacitinib, 11 mg XR multi center, randomized, treatment for RA; 2017→ongoing

Regeneron:

  • iL1, multi center, randomized, treatment for RA

Roche:  

  • ibandronate, multi center, randomized, treatment for OP
  • tocilizumab, multi center, randomized, treatment for RA; open label extension study

Sanofi Aventis:

  • sarilumab, multi center, randomized, treatment for Ankylosing Spondylitis
  • sarilumab, multi center, randomized, treatment for RA

Serono:

  • onercept, multi center, randomized, treatment for Psoriasis and Plaque Psoriasis

UCB:

  • certolizumab pegol, multi center, randomized, treatment for RA

Vertex: V

  • X-509 (JAK3) multi center, randomized, treatment for RA

Robin K Dore MD, Inc. 2025 . Powered by WordPress